ORIGINAL ARTICLE: RESEARCH

Statins induce lethal effects in acute myeloblastic lymphoma cells within 72 hours

LILLIAN P. BURKE & CYNTHIA A. KUKOLY

Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA

(Received 24 July 2007; revised 9 October 2007; accepted 17 October 2007)

Abstract
HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might induce cell death in AML cells at clinically attainable concentrations. The time and concentration dependence of HL60 and U937 cells was determined and showed that cell death was delayed. IC50 values and IC90 values determined on day 6 suggested that the sensitivity of AML cells to statins may occur at lower concentrations than previously reported. After 72 h, mevalonate did not rescue AML cells from cytotoxic concentrations of statins, suggesting that, although cell death was delayed, lovastatin induced lethal effects within 72 h. In conjunction with previously reported Phase I studies, the data presented here suggest that the high-dose, short course statins may be useful for the treatment of patients with AML.

Keywords: Acute myeloid leukemia, statins, HMG CoA reductase inhibitors, drug studies, leukemic cell lines, HL60 cells, U937 cells

Introduction
Statins are useful for the treatment of patients with hypercholesteremia and are among the most widely prescribed drugs. Meta-analyses suggest that statin treatment may decrease the risk of developing certain malignancies although recent studies have provided data conflicting with this hypothesis [1,2]. In vitro, statins induce apoptosis in both primary cells and in tumor cells derived from patients with a variety of malignancies [3]. Sensitivity to statin-induced cytotoxicity is tumor-line specific. Sensitive cells include cells derived from AML, including chemotherapy-resistant AML [4], as compared with the relative statin resistance seen in cells derived from patients with acute lymphoid leukemia [5,6]. Drug resistant cells may be more sensitive to statins than the non-drug resistant cells, suggesting that statins may be useful for the treatment of drug-resistant malignancies [4,7 – 9]. Statins induce cell death in malignant cells at concentrations that are significantly higher than those that are effective for the treatment of hypercholesteremia [10]. Cell death occurs via apoptosis and lovastatin concentrations of up to 5 μM and are required to induce apoptosis in AML cell lines and in primary AML cells [5,11,12]. Six of 7 AML cell lines had an IC50 of ≤5.3 μM when exposed to statins for 2 days [5,13]. Primary AML cells also showed a decrease in proliferation and in colony formation when exposed to statins for 2 days, although several of the cultures required lovastatin concentrations of up to 40 μM or more to effect a decrease proliferation and or colony formation. In contrast, normal hematopoietic cells are tolerant of lovastatin or atorvastatin concentrations of up to 160 μM or more [5,14,15].

These laboratory findings suggest that lovastatin concentrations of approximately 5 μM or more might be required to induce cell death in AML cells. Unfortunately, this lovastatin concentration is at the upper limits of tolerability in human studies, except when the duration of exposure is limited to four days or less [16]. Although several animal species tolerate prolonged duration of statin exposure at
concentrations of 2–4 μM [15,17], humans do not tolerate drug concentrations in this range for more than 4–7 days. In a Phase I study of lovastatin, given at up to 25–45 mg/kg/day for 7 days, the peak lovastatin concentration in any patient was reported as 3.9 μM [18]. At higher lovastatin concentrations, or with more prolonged duration of therapy, non-hematological toxicities, such as myopathy, hepatotoxicity and renal failure are dose limiting [19]. In contrast, when the lovastatin exposure was limited to a 4 day course of treatment, peak concentrations of up to 12 μM were tolerated without evidence of clinical toxicity [16]. Taken together, these studies suggest that patients might tolerate lovastatin concentrations of up to 12 μM, or possibly more, if the duration of statin exposure is limited to 4 days or less.

However, it is not known whether short courses of high concentrations of statins would be therapeutically efficacious. As a first step in examining these questions, we sought to determine the time and concentration dependence of statin-induced cytotoxicity for AML cell lines in order to determine the optimal duration of statin exposure for clinical studies in patients with AML. The results reported here support the development of clinical trials of short-course, high dose statins for the treatment of AML.

Materials and methods

Cell lines

Cell lines used were obtained from ATCC (Mannassas, VA; HL60 and U937 cells). Cells were grown in RPMI 1640 (Gibco, Carlsbad, CA, #11875–093) with 10 mM Hepes and 1 μM sodium pyruvate, supplemented with 10% fetal calf serum (FCS, Hyclone, Logan, UT). All cell lines were maintained at 37°C in a humidified atmosphere with 5% CO2.

Reagents

Mevalonate was obtained as mevalonolactone (Sigma, St. Louis, MO M4667). Stock concentrations were made in DMSO and later diluted in media or PBS prior to use in culture. Lovastatin was obtained from CalBiochem, (San Diego, CA), and was converted to the open acid form prior to use as described by Hancock [20]. The resulting lyophilized statins were resuspended in DMSO (Dimethyl sulfoxide, Catalog # D8418, Sigma, St. Louis, MO) and stored in small aliquots at −20°C until time of use. DMSO at the highest concentration used for the lovastatin treatment served as the vehicle control.

Cell proliferation

“MTS assay”: Cells were seeded in 96 well flat-bottomed plates (100 µL/well, Falcon). For all assays, we determined the number of cells to be plated so that the control cells would be experiencing log phase growth and would be at a concentration so that the assay was in the linear portion of the absorbance curve on the assay (typically 3000 cells/well). Cell proliferation assays to determine IC50 concentrations were measured using the MTS-based assay by Promega (Cell Titer96 Aqueous One Solution, Madison, WI), according to the manufacturer’s instructions. All samples were run in triplicate and absorbance recorded at 490 nm with a plate reader after incubation at 37°C for 1–3 h. Background absorbance was corrected by subtracting the absorbance values from the media alone (control) wells. This assay is dependent on intracellular metabolism, and absorbance will be decreased if cell proliferation is inhibited, or if the cells are dead or dying. All values were expressed as a percent of the control (untreated) cells unless otherwise specified. For prolonged incubations, drying of the samples was avoided by the addition of sterile, distilled water in the outer wells of microtiter plates.

Apoptosis detection

At the indicated time, the cells were harvested, stained with the Annexin-V-Fluos (Catalog # 1 828 681, Roche Diagnostics, Indianapolis, IN) and propidium iodide (PI) (Catalog P4170, Sigma, St. Louis, MO) and analyzed by flow cytometry using a Becton Dickenson Immunocytometry Systems (San Jose, CA). CellQuest software (Becton Dickenson) was used for the acquisition and analysis of data. Samples were run in duplicate with 10 000 events counted per sample. Viable cells included cells that were negative for both annexin and PI. Viable cell number was determined by cell counts multiplied by the percent of viable cells.

Determination of IC50 values

The concentrations that decreased cell proliferation by 50% (Inhibitory Concentration 50%, IC50) or by 90% (IC90 values) were determined using serial dilutions of lovastatin (typically 500–0.01 μM) and were calculated using the Graph Pad PRISM (Version 3.0; San Diego, CA). To determine rescue of cell proliferation from statins, plated cells were treated with statins alone or in the presence of mevalonate (for concentrations, see figure legends). Plates were assayed on the specified day, with day 0 being the first day of drug exposure.
Results

IC$_{50}$ values for several AML cell lines are reported to be $\leq 5 \mu$M [5]. We first attempted to verify that these concentrations were cytotoxic. After 48 h of exposure to 4 $\mu$M of lovastatin, Trypan blue uptake was seen in only 7.6% of HL60 cells (data not shown). Even at a relatively high concentration of lovastatin (50 $\mu$M), we found that only 10.7% of the cells were Trypan blue positive after 48 h of lovastatin exposure. In contrast, after 6 days of culture in the presence of lovastatin, 50 $\mu$M, 82.2% of the HL60 cells were Trypan blue positive. Similar results were seen using U937 cell exposed to 50 $\mu$M of lovastatin with 7.1% of U937 cells Trypan blue positive at day 2 and 55.6% of the U937 cells Trypan blue positive at day 6. Since significant cell death was seen late, we examined the time dependence and assay-dependence of statin-induced cytotoxicity.

Time dependence of statin-induced cytotoxicity

Proliferation assays are useful for performing replicate assays. It is well-established that statins induce apoptosis in sensitive cells [5,11,21] and apoptosis has been used to detect sensitivity to statins. Therefore, we first determined whether the time course of statin-induced cytotoxicity was the same when assayed by the proliferation assay as compared with cell count and apoptosis assays. U937 cells and HL60 cells were cultured in the presence of serial dilutions of lovastatin. The effects on cell proliferation were determined by both total cell counts [Figure 1(A)] and by the proliferation assay [Figures 1(B) and 1(C)]. Using Annexin V as a marker of apoptosis, we found that full expression of this process is delayed for at least 4–5 days as judged by either the percentage of viable cells [Figure 1(D)] or the total number of viable cells [Figure 1(E)]. In each of these assays, full lovastatin cytotoxic effects were delayed for 4–6 days, especially at lower, more clinically relevant concentrations. Therefore, the delay in evidence of cytotoxicity is not assay dependent when studied at clinically relevant concentrations of lovastatin (i.e. $<12 \mu$M).

Effect of day of assay on determination of IC$_{50}$

Since maximal cell death was seen after 4–6 days of lovastatin exposure, it was possible that determinations of cytotoxic drug concentrations at day 2 might over-estimate the statin concentrations required to inhibit cell growth and/or to induce cell death. To assess the magnitude of this effect, we compared the IC$_{50}$ values as determined at day 2, with those determined on day 6 using two cell lines, HL60 cells and U937 cells (Figure 2). When measured by proliferation, the IC$_{50}$ for HL60 was 5.1 $\mu$M, very similar to that found by Dimitroulakos et al. who reported that the IC$_{50}$ for HL60 cells was 5.3 $\mu$M when measured at day 2 [5]. However, when measured at day 6, the IC$_{50}$ for HL60 cells was 1.2 $\mu$M (a 4-fold difference). The IC$_{50}$ values for U937 cells showed the same time dependence with apparent IC$_{50}$ values of 71.1 $\mu$M when measured at day 2 and 4.5 $\mu$M at day 6 (a 15-fold difference) [Figure 2(A)].

Ideally, a drug that is cytotoxic for AML cells should induce cell death in $>90\%$ of cells. Using the same experimental data as that shown in Figure 2(A), we estimated the IC$_{90}$ values for HL60 cells and U937 cells [Figure 2(B)]. As expected, the IC$_{90}$ values for HL60 and U937 cells were markedly higher when measured at day 2 than at day 6. At day 2, the IC$_{90}$ for HL60 cells was 46 $\mu$M while at day 6, the IC$_{90}$ was 4.2 $\mu$M. The IC$_{90}$s for U937 at days 2 and 6 were 217 $\mu$M and 19.3 $\mu$M, respectively [Figure 2(B)].

Statin exposure for 48–72 h induces cell death in AML cells

Although statin-induced cytotoxicity was maximal at day 6, it was not clear whether this effect was due to

Figure 1. Time course of statin dependent effects on proliferation and AML cell viability. The time dependence of lovastatin (LST) induced effects on proliferation and apoptosis were determined in U937 or HL60 cells. Treated samples were compared with that of untreated cells. (N$\geq$ 3, one example is shown for each assay.) (A) Cells counts by day of culture, at various concentrations. Cell number was determined using a Coulter counter. Shown are total cell counts. At lower concentrations (i.e. $<15 \mu$M), differences between treated and untreated cells are best seen after at least 4 days of statin exposure. (B) Time course of changes in absorbance (MTS assay). Cell proliferation was measured using an MTS-like colorimetric assay that reflects cellular metabolism. (C) Effects of statins during the first 2 days of culture. Cells were plated at a concentration of 10,000 cells per well in order to look at the effects of lovastatin on proliferation during the first 2 days of drug exposure. These results show that lovastatin did not markedly affect proliferation during the first 2 days of statin exposure, especially at the lower concentrations studied. (D) Percentage of viable cells, by apoptosis, after lovastatin exposure, by day of culture (HL60 cells). Percentage of cells, by day, that were negative for both PI and Annexin. (E) Viable cell number. Using the same data set as shown in 1D, the number of viable cells was determined for each day of treatment by multiplying the number of cells as determined the Coulter counter by the percentage of cells negative for both annexin and PI. In each assay, the cytotoxic effects of concentrations of statins in the clinically relevant range (i.e. $5–12 \mu$M) are seen only with longer duration of statin exposure.
prolonged exposure to lovastatin, or due to delayed
evidence of cytotoxicity. To explore this question, we
used mevalonate to rescue cells from lovastatin.

Statins inhibit the enzyme, HMG-CoA reductase,
and thereby decrease the production of mevalonate
and its downstream metabolites. Mevalonate, when
added to statin-containing cultures, inhibits the cytotoxic effect of statins [11,22].

At concentrations of up to 200 μM, mevalonate alone neither increased nor decreased the proliferation of HL60 or U937 cell lines (data not shown). At 200 μM, mevalonate fully rescued both HL60 and U937 cells from the cytotoxic effects of a high concentration of lovastatin (50 μM) (Figure 3). To determine the minimum duration of lovastatin exposure needed to induce statin cytotoxicity, we cultured HL-60 and U937 cells in the presence of lovastatin. After variable durations of lovastatin exposure, mevalonate at 200 μM was added to the cultures in an attempt to rescue the cells (Figure 4). First, we defined the minimum lovastatin exposure time needed to induce lethality by exposing the cells to a high concentration of lovastatin (50 μM) and rescuing the cells with mevalonate (200 μM) after 0, 1, 2, 4, 7, 24 or 48 h of lovastatin exposure [Figure 4(A)]. The effects on cell proliferation were examined at day 6. As expected, mevalonate completely rescued cell proliferation when added to the cultures at time 0. However, after 48 h of exposure to this high concentration of lovastatin, mevalonate was not able to rescue either HL60 or U937 cells from statin-induced cytotoxicity.

We next examined the time dependence of lower concentrations of lovastatin by determining the effect of the duration of unopposed lovastatin (before mevalonate rescue) on the IC50 values. When mevalonate was added after 2 days of statin exposure, the IC50 for HL60 cells was almost the same as that seen after 6 days of unrescued exposure to statins [Figure 4(B)]. U937 cells required 72 h of statin exposure before rescue in order to have an IC50 that was similar to that seen after 6 days of statin exposure without mevalonate rescue [Figure 4(C)].

**AML cells do not recover from lovastatin exposure after 3 days**

To determine whether lovastatin induced cell death at low concentrations or merely inhibited proliferation, we examined the viability of statin-exposed cells using Trypan blue staining of HL60 cells at day 6, when rescued after various durations of statin exposure. At 12 μM of lovastatin, most of the HL60 cells were non-viable after 48 h of statin exposure as the number of viable cells that were Trypan blue negative (i.e. viable) in the treated cultures was only 10.4% that of the control cultures [Figure 5(A)]. We also looked at the ability of the AML cells to recover from lovastatin by incubating the cells for 72 h in the presence of serial dilutions of lovastatin. The cells were then rescued with mevalonate and allowed to recover for 6 days. Despite the prolonged recovery period, the IC50 values for both U937 cells and HL60 cells were similar to the IC50 values of the unrescued cells [Figure 5(B)].

**Discussion**

High dose statins may be useful for the treatment of AML, but the optimal drug concentration and duration of therapy required to induce cell death in AML cells is not known. Dimitroulakos et al. determined the IC50 values of several AML primary cells and cell lines and showed that six of seven of
these AML cell lines had IC\textsubscript{50} values between 1.0 and 5.3 µM when assayed after 2 days of lovastatin exposure [3]. Our initial studies showed that most cells appeared to be viable after 2 days of statin exposure as determined by Trypan blue staining. This finding was consistent with the original data published in other studies [5,13,23]. Statins are known to decrease cell proliferation; however, at concentrations higher than 5 µM, statins may induce apoptosis, resulting in cell death [24]. These initial studies suggested that single-agent statins might not induce cell death at clinically tolerable concentrations.

As reviewed above, Phase I studies suggest that the upper concentration of lovastatin that is clinically tolerable is approximately 4 µM for 7 days [18] or 12 µM for 4 days [16] but these concentrations are not tolerated when the duration of exposure is prolonged [19]. An alternative way to improve the therapeutic efficacy of high dose statins for the treatment of AML might be to increase the drug concentration while decreasing the duration of statin exposure. However, the ability of statins to induce cell death in AML cells after a short exposure has not been clear. In these studies, we demonstrate that lovastatin induces cell death in sensitive AML lines within 72 h of exposure to cytotoxic concentrations.

Our initial studies showed that evidence of statin-induced effects on cell proliferation and viability were delayed. Maximal cytotoxic effects were not seen for at least 4 to 6 days, depending on the particular assay (Figure 1). Delayed effects were seen in assays of proliferation and apoptosis, as well as traditional studies based on cell counts and Trypan blue staining. Delays were also seen at high concentrations of statins. The delay in evidence of statin-induced cytotoxicity affected the determination of apparent cytotoxic drug concentrations. The IC\textsubscript{50} values as determined at day 2 were 4-fold (HL60 cells) or 15-fold (U937 cells) higher than those determined at day 6 [Figure 2(A)]. The estimates of IC\textsubscript{90} values showed similar discrepancies, with a 10-fold increase in apparent required concentrations of statins when the assays were performed at day 2 as compared with day 6 [Figure 2(B)]. Thus, measurement of the IC\textsubscript{50} at day 2 overestimates the actual IC\textsubscript{50} and IC\textsubscript{90} concentrations by ½ log or more. Most significantly, the IC\textsubscript{50} and IC\textsubscript{90} values determined at day 6 predict that lovastatin will induce cell death in AML cells at clinically tolerable concentrations in contrast to the less encouraging findings when these values are determined at day 2, especially for the less sensitive U937 cells [Figure 2(A)].

Although cytotoxicity was evident at clinically tolerable concentrations at day 6, it was not clear whether this increase in sensitivity at day 6 was due to longer duration of drug exposure or due to delayed evidence of statin effects. To distinguish the effects of longer statin exposure from the effects of delayed cell death, we used mevalonate to rescue cells from statins [4]. Mevalonate alone, as a single agent, neither increased nor decreased AML cell proliferation (Figure 3). At a high concentration of lovastatin (50 µM), only 48 h of unopposed drug exposure was required to block mevalonate rescue of both HL60 and U937 cells [Figure 4(A)]. However, 50 µM lovastatin is not likely to be clinically

---

Figure 3. Effects of mevalonate (MLA) on proliferation in the presence or absence of lovastatin (lov). Cells were cultured for 6 days in the presence of lovastatin (50 µM) with or without mevalonate at the stated concentrations. Proliferation was assayed at day 6 by the MTS assay. (N = 3 for each cell line) (A) HL60 Cells (B) U937 cells.
tolerable. For this reason, we next explored the relationships among duration of lovastatin exposure before mevalonate rescue and the IC\textsubscript{50} values. These studies demonstrated that when mevalonate rescue was delayed for 48 h [HL60 cells, Figure 4(B)] or 72 h [U937 cells, Figure 4(C)], the IC\textsubscript{50} values were essentially the same as the IC\textsubscript{50} values of unrescued cells exposed to lovastatin for 6 days [Figures 4(B) and 4(C)]. These results were not assay dependent as similar results were seen using Trypan blue staining of HL60 cells exposed to clinically relevant concentrations of lovastatin [Figure 5(A)]. Therefore, although full evidence of statin-induced cell death is delayed for 5–6 days, statins induce irreversible lethal effects in AML cells within 48–72 h.

Since lovastatin inhibits cell proliferation, it was also possible that these cells were not dead but simply had stopped proliferating and did not have time to recover. To test this possibility, we exposed the AML cells to lovastatin for 72 h, then rescued the cells with mevalonate and allowed them to proliferate for a full 6 days after mevalonate rescue. Even after 6 days of mevalonate rescue, neither HL60 cells nor U937 cells were able to resume proliferation (Figure 5). Taken together, these results suggest that AML cells with sensitivity similar to HL60 and U937 cells might undergo cell death at lovastatin concentrations of 12 \( \mu \text{M} \) or less, and that this effect is irreversible within 48–72 h of exposure to cytotoxic concentrations of this drug. The clinical importance of these findings is that they imply that at least some cells will have IC\textsubscript{50} values, or even IC\textsubscript{90} values, at concentrations that might be clinically tolerable for 2–3 days (i.e. \( \leq 12 \mu \text{M} \)). Furthermore, statins at clinically tolerable concentrations do not merely inhibit cell proliferation; rather, they induce cell death. One limitation of our studies is that these have been performed only in AML cell lines. Studies in primary cells are presently ongoing; however, previous reports indicate that the statin sensitivity of primary cells corresponds well to that of AML cell lines [5].

The time dependence of statin-induced cytotoxicity has been previously noted as an incidental

Figure 4. Number of days of statin exposure required for maximal statin-induced cytotoxicity. After various durations of lovastatin exposure, mevalonate was added to the cells to rescue them from the cytotoxic effects of statins in order to determine the minimum duration of statin exposure needed to induce a cytotoxic effect. (A) Duration of lovastatin exposure required at high concentrations (50 \( \mu \text{M} \)). HL60 and U937 cells were cultured with 50 \( \mu \text{M} \) lovastatin for 0, 1, 2, 4, 7, 24 or 48 h prior to the addition of 200 \( \mu \text{M} \) Mevalonate. The culture was then incubated for 4 additional days and then assayed using the MTS-based proliferation assay (\( N \geq 3 \) for each cell line). (B and C): IC\textsubscript{50} determinations by day of rescue. Mevalonate was added on the indicated day of lovastatin treatment. IC\textsubscript{50} values were determined on day 6 (\( N = 3 \) for each cell line). (B) HL60 Cells. (C) U937 Cells.
finding in AML cells [5]. In myeloma cells, simvastatin and flustatin increase the sensitivity to cytotoxic agents in a time-dependent manner [25]. Although statins affect activation of the MAPK signaling pathway within 6 h, induction of caspase 3 is not seen for 48 h [26].

In vitro, a few days of lovastatin exposure synergistically increases the sensitivity of malignant cells to chemotherapy. This effect may be more marked in drug-resistant cell lines [4,27]. Clinically, statins seem to be well-tolerated in combination with cytotoxic agents as the toxicities are non-overlapping. A Phase I trial of pravastatin, in combination with idarubicin and cytarabine produced encouraging responses in patients with high-risk leukemia [28]. Van der Spek et al. treated patients with simvastatin 15 mg/kg/day for 7 days before chemotherapy with VAD or CHOP regimens for myeloma or lymphoma, respectively, with an overall response rate of 30% in a heavily pretreated population and minimal evident toxicity [25]. Forty-eight to 72 h of lovastatin or simvastatin exposure sensitized AML cells to cytarabine [29,30, for example]. Therefore, these preliminary clinical and laboratory studies suggest that a short course of high dose statins can be tolerated in combination with cytotoxic agents.

In summary, we found that the full cytotoxic effect of lovastatin in AML cells was not seen for at least 4–6 days after exposure to lovastatin. Despite the delayed evidence of cell death, lovastatin induces irreversible lethality after 48–72 h of drug exposure. These irreversible toxic effects occur at clinically tolerable concentrations of ≤12 μM for both HL60 and U937 cells. In conjunction with the results of Phase I studies, these results suggest that high-dose, short course statins might induce cell death in AML cells at plasma concentrations that are clinically tolerable if high dose statin exposure is limited to ≤4 days. These studies also provide theoretical support for the development of additional clinical studies to examine the tolerability and efficacy of high-dose, short-course statins for the treatment of patients with AML.

Figure 5. Effect of lovastatin pre-treatment on viability at clinically attainable concentrations. (A) Viability as assessed by Trypan blue staining: HL60 cells were treated with 1, 3 or 12 μM lovastatin on Day 0. Mevalonate (200 μM) was added to the cells on day 1, 2, 3, 4 or 5. The effects on viability determined on day 6 as measured by cell counts and Trypan blue uptake. N = 2; one example is shown. (B) Ability to recover from lovastatin after 72 h of exposure. HL60 or U937 cells were exposed to lovastatin for 72 h and then rescued with mevalonate (200 μM). They were allowed to proliferate for an additional 6 days. The IC₅₀ was determined after a total of 3 days of lovastatin exposure and 6 days of mevalonate-rescued growth, i.e. on day 9. Two separate assays were performed and the results for each are as shown (N = 2 for each cell line, with the individual samples indicated by “A” or “B”). For comparison purposes, the IC₅₀ values as determined previously are plotted (same data as Figure 2, day 6).
Acknowledgements

This work was supported, in part by grants from ECU Physicians (Physician-Scientist Award), Ladies Auxiliary of the Veterans of Foreign Wars, and by the Department of Internal Medicine, Brody School of Medicine, East Carolina University. There are no conflicts of interest.

References

1. Dale KM, Coleman CL, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74 – 80.
2. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. HMG CoA reductase inhibitors and the risk of colorectal cancer. N Engl J Med 2005;352:2184 – 2192.
3. Chan KKW, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003;9:10 – 19.
4. Maksumova L, Ohnishi K, Muratkhodjaev F, Zhang W, Pan L, Takeshita A, et al. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia 2000;14:1444 – 1450.
5. Dimitroulakos J, Noltynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999;93:1308 – 1318.
6. Hunakova L, Sedlak J, Sulikova M, Chovancova J, Duraj J, Chovara B. Human multidrug-resistant myeloid leukemia HL-60/ADR cells in vitro: resistance to the mevulonate pathway inhibitor lovastatin. Neoplasia 1997;4:366 – 369.
7. Diamond AM, Jaffe D, Murray JL, Saha A, Samuels BL, Hatfield DL, et al. Lovastatin effects on human breast carcinoma cells. Differential toxicity of an adriamycin-resistant derivative and influence on selenocysteine tRNAS. Biochem Mol Biol Int 1996;38:345 – 355.
8. Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002;43:1221 – 1228.
9. Dimitroulakos J, Yeger H. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 2002;8:326 – 333.
10. Grundy SM, Cleeman CJ, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720 – 732.
11. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508 – 519.
12. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001;15:1398 – 1407.
13. Stirewalt DL, Appelbaum FR, Willman CL, Zager RA, Banker DE. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res 2003;27:133 – 145.
14. Scheffold C, Schockter B, Leferova P, Csipai M, Glasmercher A, Huhn D, et al. Increased sensitivity of myeloid leukemia cell lines: potential of lovastatin as bone-marrow-purging agent. Acta Haematol 2000;104:72 – 79.
15. Walsh KM, Albassam MA, Clarke DE. Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. Toxicol Pathol 1996;24:468 – 476.
16. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 2006;57:155 – 164.
17. Walsh KM, Rothwell CE. Hepatic effects in beagle dogs administered atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 2 years. Toxicol Pathol 1999;27:395 – 401.
18. Thibault A, Samid D, Tompkins AC, Flig WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevulonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483 – 491.
19. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 2005;41:523 – 530.
20. Hancock JF. Prenylation and palmitoylation analysis. Methods Enzymol 1995;255:237 – 245.
21. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000;40:167 – 178.
22. Maltese WA, Sheridan KM, Repko EM, Eardman RA. Post-translational modification of low molecular mass GTP-binding proteins by isoprenoid. J Biol Chem 1990;265:2148 – 2155.
23. Clutterbuck RD, Millar BC, Powell RL, Newman A, Catovsky D, Jarman M, et al. Inhibitory effect of simvastatin on the proliferation of human myeloid leukemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol 1998;102:522 – 537.
24. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003;101:3628 – 3634.
25. van der Spiek E, Bloem AC, van de Donk NW, Boers LH, van der Griep R, Kramer MH, et al. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 2006;91:542 – 545.
26. Zhong WB, Wang CY, Chang TC, Lee WS. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 2003;144:3852 – 3859.
27. Holmberg M, Sandberg C, Nygren P, Larsson R. Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 660 kDa P-glycoprotein. Anticancer Drugs 1994;5:598 – 600.
28. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemberk E, Verstovsek S, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007;109:2999 – 3006.
29. Holstein SA, Hohl RJ. Interaction of cytochrome c arabinoside and lovastatin in human leukemia cells. Leuk Res 2001;25:651 – 660.
30. Lishner M, Bar-Sef A, Elias A, Fabian I. Effect of simvastatin alone and in combination with cytochrome c arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med 2001;49:319 – 324.